Journal of Society of Preventive Korean Medicine (대한예방한의학회지)

Society of Preventive Korean Medicine (대한예방한의학회)
권호 표지

Effect of Gongjindan, a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (2) - Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg, 1.5hr-intervals with 7-day Repeated Treatment -

  • Kwon, Oh Dae (Department of Neurology, Catholic University of Daegu School of Medicine) ;
  • Chung, Dae-Kyoo (Department of Neuropsychiatry, College of Korean Medicine, Daegu Haany University) ;
  • Park, Soo Jin (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Lee, Young Joon (Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University) ;
  • Ku, Sae Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
  • Received : 2013.03.16
  • Accepted : 2013.08.06
  • Published : 2013.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study was aim to evaluate effects of pharmacodynamics and toxicity in combination therapy of donepezil with Gongjindan. The effects of Gongjindan co-administration on the pharmacokinetics (PK) of donepezil were observed after single and 7-day repeated oral co-administration with 1.5hr-intervals, to evaluate synergic pharmacodynamics and reduce toxicity of combination therapy of donepezil with Gongjindan. Materials and Methods : After 10mg/kg of donepezil treatment, Gongjindan100mg/kg was administered with 1.5hr-intervals. The plasma were collected at 30min before administration, 30min, 1, 2, 3, 4, 6, 8 and 24hrs after end of first and last 7th donepezil treatment, and plasma concentrations of donepezil were analyzed using LC-MS/MS methods. Results : Gongjindan markedly inhibited the absorption of donepezilregardless of sample time, from 30min to 8hrs after end of first 1.5hr-interval co-administration as compared with donepezil single treated rats. Especially the absorption of donepezil was significantly decreased at 2, 4, 6 and 8hrs after co-administration as compared with donepezilsingle treated rats. Accordingly, the Cmax (-26.236%), $AUC_{0-t}$(-26.02%) and $AUC_{0-inf}$(-25.90%) of donepezil in 1.5hr-interval co-administered rats were dramatically decreased as compared with donepezilsingle treated rats, respectively. However, no meaningful changes on the plasma donepezil concentrations and pharmacokinetic parameters were detected after end of last 7th 1.5hr-interval co-administration as compared with donerezil single treated rats, except for non-significant slight increases of Tmax(16.67%) detected in co-administered rats as compared with donepezil single treated rats. Conclusion : These findings are considered as direct evidences that Gongjindan also decreased oral bioavailability of donerezil as inhibited the absorptions, when they were co-administered with 1.5hr-intervals, but they may be adapted after 7 days continuous repeated l.5hr-interval co-administration.

Keywords

References

  1. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane database of systematic reviews ( Online). 2006 (1):CD001190
  2. Rogers SL. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia and geriatric cognitive disorders.1998;9 Suppl 3:29-42
  3. Roman GC, Rogers SJ. Donepezil:aclinical review of current and emerging indications. Expert opinion on pharmacotherapy. 2004;5 (1):161-180 https://doi.org/10.1517/14656566.5.1.161
  4. Rojas-Fernandez CH. Successful use of donepezil for the treatment of dernentia with Lewy bodies. The Annals of pharmacotherapy. 2001; 35(2):202-205 https://doi.org/10.1345/aph.10192
  5. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane database of systematic reviews (Online). 2004(1):CD 004395
  6. Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezi limproves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest. 2008;133(3):677-683 https://doi.org/10.1378/chest.07-1446
  7. Riedel G, Kang SH, Choi DY, Platt B. Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behavioural brainr esearch. 2009;204(1): 217-225
  8. Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. Journal of child and adolescent psychopharmacology. 2011;21(1):43-50 https://doi.org/10.1089/cap.2010.0024
  9. PfizerCanada Inc.. PRODUCT MONOGRAPH PrARICEPT(R)(donepezil hydrochloride) Tablets 5 and 10 mg PrARICEPT RDTTM (donepezilhydrochloride) Rapidly Disintegrating Tablets 5 and 10 mg Cholinesterase Inhibitor. FDA Submission Control No: 107207.2007
  10. Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. Journal of psychopharmacology(Oxford, England). 2000; 14(4):406-408
  11. Benazzi F. Mania associated with donepezil. Journal of psychiatry & neuroscience : JPN. 1999;24(5):468-469
  12. Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatr practice. International psychogeriatrics/IPA. 2008;20(4):800-806
  13. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dementia and geriatric cognitive disorders. 2009;28(5):389-403 https://doi.org/10.1159/000255578
  14. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multipledoses. British journal of clinical pharmacology. 1998;46 Suppl 1:25-29
  15. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. British journa lof clinical pharmacology.1998;46 Suppl 1:30-34
  16. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmaco kinetics and pharmacodynamics of donepezil. Journal of clinical pharmacology. 2004;44(5): 538-542 https://doi.org/10.1177/0091270004264161
  17. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. British journal of clinical pharmacology.1998;46 Suppl 1:40-44
  18. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. British journal of clinical pharmacology.1998;46 Suppl 1: 35-39
  19. Tiseo PJ, Foley K, Friedhoff LT. The effec to fmultiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. British journal of clinical pharmacology. 1998;46 Suppl 1: 45-50
  20. Kim YH, Bae MJ. The effect of Kong Jin Dan on the lipid metabolism in rats fed high fat-diet. J East-West Med. 2001;14: 61-78
  21. Kim YS, Lee JD, Kim CH, Choi DY, Park DS, Nam SS, Kang SK. The Effect of Gongjindan Aqua-acupuncture on the CD4+ T cell count at al. in rats were administered with MTX. J Korean Acup Moxi Soc. 1999;16:179-202
  22. Choi KH, Park CS. An analysis of the Gongjindan's ingredients and its efficacy on anti-oxidation. Korea J Herbology. 2007; 22(2):51-63
  23. Seong KM, Hae RK, Song BK. The effect of Gongjin-dan on gliosis in middle cerebral artery occlusion (MCAO) rats. J Korea Oriental Int Med. 2009;30:674-684
  24. Hwang SM, Chung DK. The Effects of Kong Jin-Dan (KJD) on the Alzheimer's disease model induced by CT105. J Oriental Neuropsychiatry. 2004;15(2):103-118
  25. Jung HC, Jang HJ, Sung WY, Lee SH, Son JH, Han SH. A study of Gongjin-danin patients with milddementia of Alzheimer type. J Oriental Neuropsychiatry. 2004;15(2): 141-148
  26. Park MY, Kim JD, Ku SK. Single Oral Dose ToxicityT est of Kong-Jin-Dan, a Polyherbal Formula in ICRMice. Biomolecules & Therapeutics. 2007;15(4):245-251
  27. Lee SN, Park JH, Ku SK. Micronucleus Test of Kong-Jin-Dan, a Polyherbal Formula, in Bone Marrow Cells of Male ICR Mice. Toxicological Research. 2008;24(3): 213-218 https://doi.org/10.5487/TR.2008.24.3.213
  28. Chung DK, Kwon OD, Park SJ, Lee YJ, Ku SK. Effect of Gongjindan, a Traditional Korean Polyherbal Formula on the Pharmacokinetics Profiles of Donepezil in Male SD Rats (1). Korean Journal of Oriental Preventive Medical Society. 2013:17(1):77-88
  29. GibaldiM, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel-Dekker; 1982.
  30. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linerar trapezoidal rule method for the calculation of the area under the palsma level-time curve. Jourmal of pharmacokinetics and biopharmaceutics. 1978: 6(6):539-546 https://doi.org/10.1007/BF01062108
  31. Fox JG, Cohen BJ, Loew FM. Laboratory animal medicine. Orlando: Academic Press Inc.; 1984
  32. Tajima Y. Biological reference data book on experimental animals. Tajima Y, editor. Tokyo: Soft Science Inc.; 1989
  33. Dickinson BD. UHC drug monograph: Donepezil. UHC (University HealthSystem Consortium) Services Corporation. 1996: 1-14
  34. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, Morishita N. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Intermational jourmal of clinical pharmacology, therapy, and toxicology. 1993; 31(5):223-229
  35. Tiseo Pj, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCI following evening administration. British journal of clinical pharmacology. 1998; 46 Suppl 1:13-18
  36. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in health volunteers: a single-dose study. British journal of clinical pharmacology. 1998;46 Suppl 1:19-24
  37. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1998; 8(1):67-75 https://doi.org/10.1016/S0924-977X(97)00079-5
  38. Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T. Absorption, distriution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug metabolism and disposition: the biological fate of chernicals. 1999;27(12):1406-1414
  39. Tiseo PF, Vargas R, Perdomo CA, Friedhoff LT. An evalustion of the pharmacokinetics of donepezil HCI in patients with impaired hepatic function. British journal of clinical pharmacology. 1998; 46 Suppl 1:51-55